Tirzepatide in Canada: Mounjaro and Zepbound

Two brands, two product contexts

Mounjaro is authorized for glycemic control in adults with type 2 diabetes. Zepbound is authorized for chronic weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Product name and indication should remain explicit in clinical and coverage discussions.^[1][2]

Why tirzepatide is called a dual agonist

Tirzepatide activates GIP and GLP-1 receptors. It is related to—but not identical with—medicines that act only at the GLP-1 receptor. Mechanism alone does not establish which product is appropriate.^[1][2]

Use the comparison that matches the question

Compare Mounjaro with Ozempic for a product-level diabetes context, or Mounjaro with Wegovy to understand why ingredient and indication both matter. Neither comparison declares a universal winner.

Access follows the exact tirzepatide product

Authorization, local availability, cash price and reimbursement are separate facts. Confirm whether the prescription names Mounjaro or Zepbound and use its exact DIN for the pharmacy quote and plan inquiry.

Do not infer that stock or coverage for one tirzepatide brand applies to the other.^[3][4]